BidaskClub cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research note issued to investors on Tuesday.
FOLD has been the topic of a number of other reports. Zacks Investment Research lowered shares of Amicus Therapeutics from a hold rating to a sell rating in a report on Tuesday, December 19th. Leerink Swann restated a buy rating and issued a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Robert W. Baird restated an outperform rating and issued a $16.00 price objective on shares of Amicus Therapeutics in a report on Monday, September 25th. Bank of America raised their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a buy rating in a report on Wednesday, October 4th. Finally, Goldman Sachs Group restated a neutral rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Amicus Therapeutics currently has an average rating of Buy and a consensus target price of $18.31.
Amicus Therapeutics (FOLD) traded down $0.15 during trading on Tuesday, reaching $15.72. 2,822,208 shares of the company’s stock were exchanged, compared to its average volume of 2,250,000. The firm has a market cap of $2,610.00, a price-to-earnings ratio of -8.59 and a beta of 1.72. Amicus Therapeutics has a 12 month low of $5.07 and a 12 month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.
In related news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the sale, the insider now directly owns 69,184 shares in the company, valued at approximately $940,210.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John F. Crowley sold 449,295 shares of Amicus Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the sale, the chief executive officer now owns 380,723 shares in the company, valued at $5,455,760.59. The disclosure for this sale can be found here. Insiders sold a total of 718,920 shares of company stock worth $10,263,669 over the last 90 days. Company insiders own 3.40% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Sage Capital Advisors llc acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $154,000. GSA Capital Partners LLP acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $309,000. Iguana Healthcare Management LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $905,000. Sterling Capital Management LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $218,000. Finally, Neuberger Berman Group LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $196,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.